Acquisition Announced Sponsor buyer
Teva Pharmaceuticals acquisition of Emalex Biosciences
US$700m consideration
Announced 29 Apr 2026
Advisers
Emalex Biosciences
Target
- Financial adviser
- PHCP
- Legal adviser
Teva Pharmaceuticals
Acquirer
- Financial adviser
- Legal adviser
- Target
- Emalex Biosciences
- Acquirer
- Teva Pharmaceuticals
- Sponsor
- Teva Pharmaceutical Industries
- Target based in
- United States
- Buyer based in
- United States
- Sector
- Pharma
- Tags
- Pharma, Biotech
In the league tables
Similar deals
- Otsuka acquisition of Transcend Therapeutics Mar 2026 · US$700m · Biotech
- UCB acquisition of Neurona Therapeutics Apr 2026 · US$650m · Biotech
- Zymeworks acquisition of Theravance Biopharma Jun 2026 · US$929m · Pharma
- Eli Lilly and Company acquisition of Ventyx Biosciences Jan 2026 · US$1.2bn · Biotech
- Amneal Pharmaceuticals acquisition of Kashiv BioSciences Apr 2026 · US$375m · Biotech
Sources
- 2026 Centerview Partners: Financial Advisor on its sale to Teva centerviewpartners.com
- 29 Apr 2026 Press release (EX-99.2, exhibit), Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience sec.gov

